Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Billy Strings revealed that he wants to set his late mother’s poetry to music for a potential new album during an extensive interview about drug use and addiction on the Dopey podcast. Strings’ mother ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Recursion ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Performances in N.Y.C. Georg Friedrich Haas has written a piece of almost ridiculous scale and complexity. The effect is awe-inspiring. Georg Friedrich Haas has written a piece of almost ridiculous ...

Hamza is a gaming enthusiast and a Writing Specialist from Pakistan. A firm believer in Keyboard/Mouse supremacy, he will play Tekken with WASD if you let him. He has been writing about games since ...

We recently published 12 Best Healthcare Stocks to Buy Under $30. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...